<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and vildagliptin, have been clearly demonstrated by a very large number of clinical trials </plain></SENT>
<SENT sid="2" pm="."><plain>Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome </plain></SENT>
<SENT sid="4" pm="."><plain>The low rate of hypoglycemic events seen in <z:hpo ids='HP_0000001'>all</z:hpo> studies confirms the <z:chebi fb="105" ids="17234">glucose</z:chebi> dependent action of incretins </plain></SENT>
</text></document>